Raising the Bar: The Curative Potential of Human Cancer Immunotherapy
Cet article passe en revue les perspectives offertes par les récents développements d'immunothérapies, notamment dans le mélanome et le cancer du rein, pour les divers cancers épithéliaux
Immunotherapy with interleukin-2 can cure 5 to 10% of patients with metastatic melanoma and renal cancer. Recent adoptive cell transfer (ACT) immunotherapies have improved cure rates in metastatic melanoma to 20 to 40%. Genetic engineering of T cells to express conventional alpha/beta T cell receptors or antibody-based chimeric antigen receptors provides an opportunity to extend ACT to patients with common epithelial cancers.